Goff Brian's Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Mar 3, 2026
- Accession no.
- 0001439222-26-000044
- Filed
- Mar 3, 2026
- Trade date
- Mar 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market sales total $522.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goff BrianCIK 0001546216 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Common stock | MOption exerciseAcquired | +8,500 | $0.00 | $0 | 151,603 | Direct | |
| Mar 2, 2026 | Common stock | SSaleDisposed | −3,870 | $28.96 | −$112,075.2 | 147,733 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseAcquired | +18,000 | $0.00 | $0 | 165,733 | Direct | |
| Mar 2, 2026 | Common stock | SSaleDisposed | −8,267 | $28.96 | −$239,412.32 | 157,466 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseAcquired | +13,000 | $0.00 | $0 | 170,466 | Direct | |
| Mar 2, 2026 | Common stock | SSaleDisposed | −5,918 | $28.96 | −$171,385.28 | 164,548 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | Common stock | AGrant or awardAcquired | +48,000 | $0.00 | $0 | 48,000 | Direct | |
| Mar 1, 2026 | Common stock | AGrant or awardAcquired | +174,000 | $0.00 | $0 | 174,000 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseDisposed | −8,500 | $0.00 | $0 | 0 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseDisposed | −18,000 | $0.00 | $0 | 18,000 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseDisposed | −13,000 | $0.00 | $0 | 26,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.